Bedell Frazier Investment Counselling LLC Makes New $618,000 Investment in Pfizer Inc. (NYSE:PFE)

Bedell Frazier Investment Counselling LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,281 shares of the biopharmaceutical company's stock, valued at approximately $618,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. United Bank raised its holdings in Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 1,277 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Pfizer by 7.4% in the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company's stock valued at $2,971,000 after acquiring an additional 7,076 shares in the last quarter. Tradition Wealth Management LLC lifted its holdings in Pfizer by 4.5% in the 3rd quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company's stock worth $734,000 after purchasing an additional 1,099 shares during the last quarter. Bellevue Group AG boosted its position in Pfizer by 59.2% during the third quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company's stock worth $4,083,000 after purchasing an additional 52,461 shares during the period. Finally, Semmax Financial Advisors Inc. raised its position in shares of Pfizer by 3.2% in the third quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company's stock valued at $2,695,000 after purchasing an additional 3,185 shares during the period. Institutional investors own 68.36% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PFE shares. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Bank of America reiterated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Price Performance

PFE traded down $0.82 during midday trading on Tuesday, reaching $24.53. 54,333,514 shares of the company's stock were exchanged, compared to its average volume of 39,155,961. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $26.05 and a two-hundred day simple moving average of $26.88. The firm has a market capitalization of $139.09 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.